Gelesis Holdings

Gelesis Holdings, Inc. operates as a biotechnology company. The firm engages in developing novel category of therapies for weight management and gut related chronic diseases. The company was founded on February 15, 2006 by Yishai Zohar and is headquartered in Boston, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Gelesis Holdings, Inc. operates as a biotechnology company. The firm engages in developing a novel category of therapies for weight management and gut related chronic diseases. The company was founded on February 15, 2006 and is headquartered in Boston, MA.

BOSTON--(BUSINESS WIRE)---- $GLS #earnings--A new paper published today in Cell Reports Medicine suggests that weight loss resulting from Gelesis' superabsorbent hydrogel treatment is not only a result of its space-occupying properties; the mechanical composition and structure of the material may have notable benefits for gut and metabolic health. The continued rise in obesity and type 2 diabetes has led to the increasing prevalence of fatty liver disease worldwide and highlights the urgent need for therapies tha.

Cell Reports Medicine Publication Demonstrates How Gelesis' Oral Therapeutic Hydrogel Promotes Weight Loss and Metabolic Health by Targeting the Gut-Liver Axis in Pre-Clinical Studies

BOSTON--(BUSINESS WIRE)---- $GLS #earnings--Gelesis, the maker of Plenity for weight management, presented a late-breaking poster presentation at the American Diabetes Association's (ADA) 2023 annual meeting showing the real-world effectiveness of the company's oral superabsorbent hydrogel across 894 people who were prescribed Plenity for weight management. Consistent with previous clinical studies, responders demonstrated clinically significant weight loss at 6 months. Plenity is an orally administered, non-stim.

Gelesis' Oral Treatment for Weight Management Showed Real-World Effectiveness in New Data Presented at the American Diabetes Association's Annual Conference

NEW YORK--(BUSINESS WIRE)--The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Gelesis Holdings, Inc. (the “Company”) — ticker symbol GLS — from the NYSE. Trading in the Company's common stock will be suspended immediately. NYSE Regulation reached its decision to delist the Company's common stock pursuant to Section 802.

NYSE to Suspend Trading Immediately in Gelesis Holdings, Inc. (GLS) and Commence Delisting Proceedings

BOSTON--(BUSINESS WIRE)---- $GLS #earnings--Gelesis Holdings, Inc. (NYSE: GLS) (“Gelesis” or the “Company”), the maker of Plenity for weight management, today reported financial results for the year ended December 31, 2022. Plenity is a novel orally administered, FDA-cleared weight management therapy that helps people feel satisfied with smaller portions, so they can eat less and lose weight, while still enjoying the foods they love.

Gelesis Reports Fourth Quarter and Full Year 2022 Results

BOSTON--( BUSINESS WIRE )--Gelesis (NYSE: GLS), the maker of Plenity for weight management, today announced that the Company will participate in the 25th Annual ICR Conference in Orlando, Florida on Monday, January 9, 2023.

Gelesis to Participate in the 25th Annual ICR Conference

NEW YORK--( BUSINESS WIRE )--The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the warrants of Gelesis Holdings, Inc. (the “Company”), each whole warrant exercisable for one share of common stock — ticker symbol GLS WS — from the NYSE. Trading in the Company's warrants will be suspended immediately. Trading in the Company's common stock — ticker symbol GLS — will continue on the NYSE.

NYSE to Suspend Trading Immediately in Warrants of Gelesis Holdings, Inc. (GLS WS) and Commence Delisting Proceedings

BOSTON--( BUSINESS WIRE )--Gelesis Holdings, Inc. (NYSE: GLS) (“Gelesis” or the “Company”), the maker of Plenity for weight management, today announced that its Chief Operating & Commercial Officer, David Pass, Pharm.D., will be featured in a panel discussion at Wolfe Research's virtual Consumer Growth Conference.

Gelesis Reports Upcoming Participation in Wolfe Research's Annual Consumer Growth Conference

BOSTON--( BUSINESS WIRE )--Gelesis Holdings Inc. (NYSE: GLS) (“Gelesis” or the “Company”) today noted that on November 16, 2022, the Company received a notification letter (the “Notice”) from the New York Stock Exchange (the “NYSE”) advising that it was not in compliance with the continued listing standard set forth in Section 802.01B of the NYSE Listed Company Manual because its total market capitalization was less than $50 million over a 30 trading-day period and its stockholders' equity was less than $50 million over a separate 30 trading-day period. The Company's common stock will continue to be listed and traded on the NYSE during the Cure Period referred to below, subject to the Company's compliance with other NYSE continued listing standards.

Gelesis Receives Notice of NYSE Market Capitalization Listing Rule Non-Compliance

Gelesis Holdings, Inc. (NYSE:GLS ) Q3 2022 Earnings Conference Call November 14, 2022 8:30 AM ET Company Participants Anna Kate Heller - IR Yishai Zohar - Founder and CEO Elliot Maltz – CFO Conference Call Participants Daniel Grosslight - Citi Operator Hello, and welcome to the Gelesis Third Quarter 2022 Earnings Conference Call. My name is Elliot, and I'll be coordinating your call today.

Gelesis Holdings, Inc. (GLS) Q3 2022 Earnings Call Transcript

BOSTON--( BUSINESS WIRE )--Gelesis Holdings, Inc. (NYSE: GLS) (“Gelesis” or the “Company”), the maker of Plenity for weight management, today reported financial results for the third quarter of 2022. Plenity is a novel orally administered, FDA-cleared weight management therapy that helps people feel satisfied with smaller portions, so they can eat less and lose weight, while still enjoying the foods they love. Plenity is the only FDA-cleared aid for weight management for people with a BMI as low as 25, up to a BMI of 40, with the largest addressable market of any prescription weight management approach on the market today.

Gelesis Reports Third Quarter 2022 Results

BOSTON--(BUSINESS WIRE)--Gelesis Holdings, Inc. (NYSE:GLS) (“Gelesis” or the “Company”), the maker of Plenity® for weight management, today announced that the Company will report financial results for the third quarter ended September 30, 2022, on November 14, 2022 prior to the market open.

Gelesis to Report Third Quarter 2022 Financial Results on November 14, 2022

BOSTON--(BUSINESS WIRE)--Gelesis Holdings Inc. (NYSE: GLS) (“Gelesis” or the “Company”) today noted that the Company received a notification letter from the New York Stock Exchange (the “NYSE”) advising that because the average closing price of the Company's common stock was less than $1.00 over a consecutive 30 trading-day period, it is not in compliance with Section 802.01C of the NYSE Listed Company Manual.

Gelesis Receives Notice of NYSE Trading Share Price Listing Rule Non-Compliance

BOSTON--(BUSINESS WIRE)--Gelesis Holdings Inc. (NYSE: GLS) (“Gelesis” or the “Company”) the maker of Plenity for weight management, today released new data at Obesity Week in San Diego.

Data Presented at Obesity Week Demonstrate that Gelesis Investigational Clinical-Stage Oral Superabsorbent Hydrogel Gel-B Preferentially Enhances the Growth of Akkermansia muciniphila in Preclinical Models Compared to Prebiotics

BOSTON--(BUSINESS WIRE)--Gelesis Holdings Inc. (NYSE: GLS) (“Gelesis” or the “Company”) the maker of Plenity for weight management, today announced Dr. Frank Greenway will give an oral presentation at Obesity Week in San Diego, on Wednesday, November 2 at 4:00pm PDT.

Dr. Frank Greenway to Present Data from the LIGHT-UP Study with Gelesis' Oral Hydrogel Treatment GS200 at Obesity Week

BOSTON--(BUSINESS WIRE)--Gelesis Holdings Inc. (NYSE: GLS) (“Gelesis” or the “Company”), the maker of Plenity for weight management, today announced that Yishai Zohar, Founder and Chief Executive Officer, Elliot Maltz, Chief Financial Officer, and David Pass, Chief Operating and Commercial Officer, will participate in the Jefferies Virtual Fitness & Wellness Summit on Monday, September 12, 2022. The Company will host a fireside chat at 9:30 a.m. ET. The live webcast can be accessed on the “

Gelesis to Participate in the Jefferies Virtual Fitness & Wellness Summit

BOSTON--(BUSINESS WIRE)--Gelesis Holdings Inc. (NYSE: GLS) (“Gelesis” or the “Company”) the maker of Plenity for weight management, today released a poster presentation at the International Congress of Endocrinology in Singapore. The LIGHT-UP study evaluated the safety and efficacy of GS200, an investigational oral hydrogel, which was designed to emulate the properties of ingested raw vegetables, with slightly different mechanical properties compared to Plenity (GS100). The LIGHT-UP study was c

Clinical Data from the LIGHT-UP Study Presented at the International Congress of Endocrinology Suggests New Gelesis Oral Hydrogel May Improve Insulin Sensitivity and Favorably Impact Metabolic Syndrome

BOSTON--(BUSINESS WIRE)--Gelesis Holdings Inc. (NYSE: GLS) (“Gelesis” or the “Company”) the maker of Plenity for weight management, today announced that the Company is participating in a fireside chat with IPO Edge today at 2:00 PM ET. The fireside chat will be hosted by Yishai Zohar, Founder and Chief Executive Officer, Elliot Maltz, Chief Financial Officer, and David Pass, Chief Operating and Commercial Officer, who will discuss, among other things: Gelesis' commercial product, Plenity, a nat

Gelesis to Participate in Fireside Chat with IPO Edge Today at 2:00 PM ET

Gelesis Holdings, Inc. (NYSE:GLS ) Q2 2022 Earnings Conference Call August 15, 2022 8:30 AM ET Company Participants Anna Heller - IR Yishai Zohar - Founder & CEO Elliot Maltz - CFO David Pass - COO & CCO Conference Call Participants Operator Hello, everyone. And welcome to the Gelesis' Second Quarter 2022 Earnings Conference Call.

Gelesis Holdings, Inc. (GLS) CEO Yishai Zohar on Q2 2022 Results - Earnings Call Transcript

BOSTON--(BUSINESS WIRE)--Gelesis (NYSE: GLS), the maker of Plenity for weight management, today reported financial results for the second quarter of 2022. “We are seeing both consumers and clinicians embracing Plenity, with continued growth in both of our distribution channels. We are excited by the fact that consumers are ordering quarterly kits at the start of their treatment journey as well as by our refill rates,” said Yishai Zohar, Founder and CEO of Gelesis. “There has been incredible mom

Gelesis Reports Second Quarter 2022 Results

BOSTON--(BUSINESS WIRE)--Gelesis Holdings, Inc. (NYSE:GLS) (“Gelesis” or the “Company”), the maker of Plenity® for weight management, today announced that the Company will report financial results for the Second Quarter ended June 30, 2022, on August 15, 2022 prior to the market open. Gelesis management will host a live conference call and webcast at 8:30 a.m. ET on the same day to discuss the results. The live call can be accessed via webcast on the “Events & Presentations” section of the

Gelesis to Report Second Quarter 2022 Financial Results on August 15, 2022

BOSTON--(BUSINESS WIRE)--Gelesis announced today that Ro, a leading and rapidly growing U.S. direct-to-patient healthcare company, has placed a $15 million pre-paid order for the company's commercial product for weight management, Plenity®. This is in addition to previous Plenity pre-orders from Ro totaling $40 million. Gelesis launched the first wave of its national broad awareness media campaign for Plenity on January 31, 2022, which corresponded with record high levels of web traffic and pre

Gelesis Announces Additional $15 Million Pre-Order for Plenity®, Bringing Total Pre-Paid Orders from Ro for Plenity to $55 Million

BOSTON--(BUSINESS WIRE)--Gelesis (NYSE: GLS), the maker of Plenity for weight management, presented new findings about the role of language in obesity and diabetes scientific literature at the American Diabetes Association's annual conference. The study sought to understand the extent to which person-first language, or language that identifies people as people as individuals first before their diagnosis, is used in scientific articles. Person-first language (e.g. referring to a person with diab

Over the Past Decade, Person-First Language Was Used in Only About Half of Diabetes-Focused Articles and Fewer than 1% of Obesity Articles, Finds New Study

BOSTON--(BUSINESS WIRE)--Gelesis (NYSE: GLS), the maker of Plenity for weight management, presented new preclinical data showing weight loss and additional metabolic benefits in mice receiving a microbiota transplant from another group of mice, treated with one of the company's proprietary hydrogels. These metabolic benefits occurred while both groups of mice, the donors of the microbiota transplant and the recipient mice, were on a high fat, high carbohydrate diet typically causing rapid weigh

Microbiota Transplantation Demonstrates How Gut Bacteria Contributes to Weight Loss and Beneficial Metabolic Effects with Gelesis' Proprietary Hydrogel

BOSTON--(BUSINESS WIRE)--Gelesis (NYSE: GLS), the maker of Plenity for weight management, today announced that Yishai Zohar, Founder and Chief Executive Officer, Elliot Maltz, Chief Financial Officer, and David Pass, Chief Operating and Commercial Officer, will participate in two upcoming investor conferences: Wednesday, May 25, 2022: UBS Global Healthcare Conference: Gelesis will host a presentation beginning at 8:30 a.m. Eastern Time. The presentation will be webcast live here and on the Comp

Gelesis to Participate in Upcoming Investor Conferences

Gelesis Holdings, Inc. (NYSE:GLS ) Q1 2022 Earnings Conference Call May 1, 2022 4:30 PM ET Company Participants Yishai Zohar – Founder and Chief Executive Officer Elliot Maltz – Chief Financial Officer David Pass – Chief Operating and Commercial Officer Conference Call Participants Ellie Merle – UBS Operator Good afternoon, everyone, and thank you for participating in today's conference call to discuss Gelesis' financial results for the fiscal quarter ended March 31, 2022. Joining us today are Yishai Zohar, Founder and CEO of Gelesis; and Elliot Maltz, CFO of Gelesis.

News for Gelesis Holdings Stock (GLS)